Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Toffoli, Sébastien ^a   Bar, Isabelle ^a   Abdel Sater, Fadi ^a   Delrée, Paul ^a   Hilbert, Pascale ^a   Cavallin, Frédéric ^a   Moreau, Fabrice ^b   Van Criekinge, Wim ^b   Lacroix Triki, Magali ^c   Campone, Mario ^d   Martin, Anne Laure ^e   Roché, Henri ^c   Machiels, Jean Pascal ^f   Carrasco, Javier ^g   Canon, Jean Luc ^g  

^a INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

^b MDxHealth   (Belgium)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d UMR INSERM U892 CNRS 6299   (France)

^e UNICANCER   (France)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Grand Hospital de Charleroi   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; AMPLICON; ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; ARTICLE; CANCER RECURRENCE; CHROMOSOME 17Q; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA METHYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROMOTER REGION; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; VALIDATION STUDY; BREAST TUMOR; CHROMOSOME 17; FEMALE; GENETICS; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHROMOSOMES, HUMAN, PAIR 17; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENES, BRCA1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84964696881     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0466-y     Document Type: Article

References (54)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
3. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272.
4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
5. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
6. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A: Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010, 36:206-215.
7. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N: Triple-negative breast cancer-current status and future directions. Ann Oncol 2009, 20:1913-1927.
8. Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM: Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 2011, 48:520-522.
9. Robertson L, Hanson H, Seal S, Warren-PerryM, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N: BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 2012, 106:1234-1238.
10. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
11. Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y, Pietenpol J: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
12. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153.
13. Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC: An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011, 22:1561-1570.
14. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA: Poly (ADP-Ribose) polymerase inhibition: "targeted" therapy for triplenegative breast cancer. Clin Cancer Res 2010, 16:4702-4710.
15. Stefansson OA: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009, 11:R47.
16. Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM: Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Gene Chromosome Cancer 2011, 50:71-81.
17. Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM: Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 2009, 116:479-489.
18. Jönsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR, Greshock JD, Luts L, Olsson H, Rahman N, StrattonM, RingnérM, Borg Å, Weber BL: Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005, 65:7612-7621.
19. MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW: The Database of Genomic Variants: a curated collection of structural variation in the human genome. Nucleic Acids Res 2014, 42:D986-D992.
20. Herman JG, GraffJR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay formethylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826.
21. Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M: BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010, 28:e563-e564. author reply e565-566.
22. The Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
23. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N: The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
24. Koh JLY, Brown KR, Sayad A, Kasimer D, Ketela T, Moffat J: COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines. Nucleic Acids Res 2012, 40:D957-D963.
25. Schmidt EE, Pelz O, Buhlmann S, Kerr G, Horn T, Boutros M: GenomeRNAi: a database for cell-based and in vivo RNAi phenotypes, 2013 update. Nucleic Acids Res 2013, 41:D1021-D1026.
26. Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee M-C, Guan A, Hesley JA, Miller SC, Cromwell EF, Solow-Cordero DE, Meyer T, Cimprich KA: A Genome-wide siRNA Screen Reveals Diverse Cellular Processes and Pathways that Mediate Genome Stability. Mol Cell 2009, 35:228-239.
27. Hurov KE, Cotta-Ramusino C, Elledge SJ: A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. Genes Dev 2010, 24:1939-1950.
28. Slabicki M, Theis M, Krastev DB, Samsonov S, Mundwiller E, Junqueira M, Paszkowski-Rogacz M, Teyra J, Heninger A-K, Poser I, Prieur F, Truchetto J, Confavreux C, Marelli C, Durr A, Camdessanche JP, Brice A, Shevchenko A, Pisabarro MT, Stevanin G, Buchholz F: A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol 2010, 8:e1000408.
29. Takazawa K, Tsuchiya H, Yoshimichi U, Kanazawa Y, Ii S, Tomita K: Expression analysis for the identification of genes involved in acquired resistance to cisplatin in osteosarcoma cells. Cancer Genomics Proteomics 2006, 3:373-381.
30. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
31. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW: Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000, 21:1761-1765.
32. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005, 65:10692-10699.
33. Ali A, Iau P, Sng J-H: Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours. Med Oncol 2011, 28:64-66.
34. Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G: BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression. Virchows Arch 2012, 461:305-312.
35. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg Å, Kallioniemi O-P: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57:1222-1227.
36. Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM: Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013, 108:2172-2177.
37. Bol GM, Suijkerbuijk KP, Bart J, Vooijs M, van der Wall E, van Diest PJ: Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 2010, 57:363-370.
38. Cancer Genome Atlas Research N: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
39. Bermudo R, Abia D, Benitez D, Carrió A, Vilella R, Ortiz ÁR, Thomson TM, Fernández PL: Discovery of genomic alterations through coregulation analysis of closely linked genes: a frequent gain in 17q25.3 in prostate cancer. Ann NY Acad Sci 2010, 1210:17-24.
40. Zweemer RP, Ryan A, Snijders AM, Hermsen MA, Meijer GA, Beller U, Menko FH, Jacobs IJ, Baak JP, Verheijen RH, Kenemans P, van Diest PJ: Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest 2001, 81:1363-1370.
41. Leunen K, Gevaert O, Daemen A, Vanspauwen V, Michils G, De Moor B, Moerman P, Vergote I, Legius E: Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways. Hum Mutat 2009, 30:1693-1702.
42. Wen Y, Ho A, Patil S, Akram M, Catalano J, Eaton A, Norton L, Benezra R, Brogi E: Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Res Treat 2012, 135:93-102.
43. Marchiò C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DSP, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A: Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009, 219:16-24.
44. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkila P, Aittomaki K, Blomqvist C, Loman N, Malmstrom P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A: Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010, 12:R42.
45. Prat A, Adamo B, Cheang MCU, Anders CK, Carey LA, Perou CM: Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013, 18:123-133.
46. Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A, Aldaz CM: Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 2007, 5:881-890.
47. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, Vallot C, Pierron G, Radvanyi F, Delattre O: Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 2008, 68:7165-7175.
48. Natrajan R, Mackay A, Wilkerson P, Lambros M, Wetterskog D, Arnedos M, Shiu K-K, Geyer F, Langerod A, Kreike B, Reyal F, Horlings H, van de Vijver M, Palacios J, Weigelt B, Reis-Filho J: Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res 2012, 14:R53.
49. Brockschmidt C, Hirner H, Huber N, Eismann T, Hillenbrand A, Giamas G, Radunsky B, Ammerpohl O, Bohm B, Henne-Bruns D, KalthoffH, Leithauser F, Trauzold A, Knippschild U: Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo. Gut 2008, 57:799-806.
50. Hirner H, Gunes C, Bischof J, WolffS, Grothey A, Kuhl M, Oswald F, Wegwitz F, Bosl MR, Trauzold A, Henne-Bruns D, Peifer C, Leithauser F, Deppert W, Knippschild U: Impaired CK1 delta activity attenuates SV40-induced cellular transformation in vitro and mouse mammary carcinogenesis in vivo. PLoS One 2012, 7:e29709.
51. Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL, Wang C, Teicher BA: Identification of genes expressed in malignant cells that promote invasion. Cancer Res 2003, 63:8939-8947.
52. Chin L-S, Raynor MC, Wei X, Chen H-Q, Li L: Hrs Interacts with Sorting Nexin 1 and Regulates Degradation of Epidermal Growth Factor Receptor. J Biol Chem 2001, 276:7069-7078.
53. Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, Tennen RI, Paredes S, Young NL, Chen K, Struhl K, Garcia BA, Gozani O, Li W, Chua KF: SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012, 487:114-118.
54. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 2012, 14:R79.